KCNN4 (Potassium Calcium-Activated Channel Subfamily N Member 4), also known as SK4 or IK1 (Intermediate-Conductance Calcium-Activated Potassium Channel 4), is an intermediate-conductance calcium-activated potassium channel that plays critical roles in immune cell activation, erythrocyte volume regulation, epithelial secretion, and neuroinflammation. Originally identified in erythrocytes and immune cells, KCNN4 has emerged as an important player in neurodegenerative diseases through its functions in microglia, astrocytes, and peripheral immune cells that communicate with the central nervous system[1].
KCNN4 belongs to the KCNN family (also known as SK/IK family) of calcium-activated potassium channels. Unlike the small-conductance KCNN1-3 channels, KCNN4 exhibits intermediate conductance (~20-80 pS), placing it between the small and large conductance channels. This unique property, along with its expression pattern in non-neuronal cells, makes KCNN4 a distinct therapeutic target for modulating immune function and neuroinflammation in neurodegenerative diseases[2].
| Property | Value |
|---|---|
| Gene Symbol | KCNN4 |
| Full Name | Potassium Calcium-Activated Channel Subfamily N Member 4 |
| Aliases | SK4, IK1, KCa3.1 |
| Chromosome | 19q13.2 |
| NCBI Gene ID | 3782 |
| Ensembl ID | ENSG00000104970 |
| UniProt ID | Q9UQM4 |
| OMIM | 604270 |
| Protein Type | Ion channel (intermediate-conductance Ca²⁺-activated K⁺) |
| Expression | Erythrocytes, immune cells, brain (glia), salivary glands |
| Associated Diseases | Multiple sclerosis, neuroinflammation, immune disorders |
KCNN4 shares the typical six-transmembrane domain structure:
Like other KCNN channels, KCNN4 is regulated by calmodulin[3]:
KCNN4 forms functional tetramers:
KCNN4 is critical for immune cell activation[4]:
T lymphocytes:
B lymphocytes:
NK cells:
Dendritic cells[5]:
KCNN4 regulates erythrocyte volume and hydration[6]:
In salivary glands and other epithelia:
In the central nervous system[7]:
Microglia:
Astrocytes[8]:
KCNN4 contributes to neuroinflammatory processes[9]:
Microglial activation:
Neuroinflammation in AD:
Neuroinflammation in PD:
KCNN4 plays a role in demyelinating diseases[10]:
T cell involvement:
Demyelination:
KCNN4 contributes to chronic pain states[11]:
Sensory neurons:
Immune contribution:
KCNN4 in post-injury responses:
KCNN4 is activated by intracellular Ca²⁺:
KCNN4 interacts with multiple pathways:
| Pathway | Interaction | Effect |
|---|---|---|
| T cell receptor | Essential for activation | Immune response |
| Calcium signaling | Modulates Ca²⁺ influx | Cellular activation |
| Cytokine production | Regulates release | Inflammation |
| Cell volume | Controls flux | Volume regulation |
KCNN4 can be pharmacologically modulated[12]:
Blockers:
Applications:
| Approach | Development Stage | Application |
|---|---|---|
| TRAM-34 | Preclinical | MS, neuroinflammation |
| Senicapoc | Clinical (sickle cell) | Inflammatory diseases |
| KCNN4 activators | Research | Limited application |
| Gene therapy | Early research | Channel restoration |
Challenges:
KCNN4 interacts with multiple components:
| Component | Interaction | Function |
|---|---|---|
| Calmodulin | Direct binding | Calcium sensing |
| T cell receptor | Essential | Immune activation |
| Cytokine pathways | Modulates | Inflammation |
| Calcium channels | Electrical coupling | Cellular activation |
Stocker M, et al. KCNN channels (SK/IK). Nature Reviews Neuroscience. 2004. ↩︎
Shah NH, et al. KCa channels in neurodegeneration. Nature Reviews Neuroscience. 2018. ↩︎
Ishii TM, et al. KCNN4 structure and function. Journal of Physiology. 2018. ↩︎
Mori A, et al. KCNN4 in immune cell activation. Immunology. 2021. ↩︎
Kim D, et al. KCNN4 in dendritic cell function. European Journal of Immunology. 2021. ↩︎
Huang Y, et al. KCNN4 in erythrocyte function. Blood. 2020. ↩︎
Kaushal V, et al. KCNN4 in glial function and neuroinflammation. Glia. 2019. ↩︎
Liu Y, et al. KCNN4 in astrocyte function. Glia. 2020. ↩︎
Weng J, et al. KCNN4 in microglial activation. Journal of Neuroscience. 2017. ↩︎
Zhang W, et al. KCNN4 and demyelination. Multiple Sclerosis. 2020. ↩︎
Yang J, et al. KCNN4 and neuropathic pain. Pain. 2019. ↩︎
Chen X, et al. Targeting KCNN4 in inflammatory diseases. Pharmacological Reviews. 2022. ↩︎